Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
Date:3/22/2013

HAYWARD, Calif., March 22, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus," has been selected as an oral presentation and will be presented at the 10th International Congress on Systemic Lupus Erythematosus by Dr. Morton Scheinberg , a rheumatologist at the Hospital Abreu Sodre Pesquisa Clinica in Sao Paulo, Brazil, on April 20, 2013.

Additionally, a poster entitled "Clinical Experience in Latin America With Blisibimod Amongst Subjects with Active, Moderate-to-Severe Systemic Lupus Erythematosus: Data From The Phase 2b PEARL-SC Study," will be presented by Dr. Scheinberg as part of the conferences Guided Poster Tours on April 19, 2013.

The poster will be available on www.anthera.com.

About Blisibimod and PEARL-SC

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF inhibitors potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a selective inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.  The PEARL-SC Phase 2 study was designed as a ran
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
2. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
9. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
10. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015  The annual customer satisfaction survey of ... EMR as #1 across all specialties. Every year, ... conducts a poll of EHR users and publishes an ... Praxis EMR topped 348 other systems, ... based criteria used by Black Book. In addition to ...
(Date:5/29/2015)... 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... is delighted to announce its financial results for ... includes revenue for three months of $2,180,276 and ... advanced wound care product sales for the three ... to $1,742,672 compared to $1,400,065 for the same ...
(Date:5/29/2015)... 2015 Amgen (NASDAQ: AMGN ) ... 3, global, randomized, placebo-controlled trials evaluating AMG 416, ... hyperparathyroidism (SHPT) in patients with chronic kidney disease ... endpoint, demonstrating that a greater proportion of patients ... than 30 percent reduction in parathyroid hormone (PTH) ...
Breaking Medicine Technology:Praxis EMR Ranks #1 for Physician Satisfaction in Black Book's 2015 Survey of Solo and Small Practices 2Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7
... 14, 2011 The Infectious Disease Research Institute (IDRI) ... from the Bill and Melinda Gates Foundation for "Chemical ... tuberculosis." The purpose of the grant is to identify ... drug development, with the ultimate goal of producing new ...
... Puritan Medical Products Company, the leading manufacturer of ... America, has announced the introduction of a new ... HydraFlock ™ and UltraFlock™ swabs both offer superior ... Both products are patent pending in ...
Cached Medicine Technology:IDRI Awarded Grant from Bill and Melinda Gates Foundation to Identify Candidates for Novel TB Drugs 2Puritan Medical Products Introduces New Patent Pending Flocked Swab Technology 2
(Date:5/29/2015)... Abington Hospital – Jefferson Health ... hospitals in the nation to join the ... and work toward achieving the Baby-Friendly USA© designation. ... on maternity care practices leading to Baby-Friendly designation. ... Prevention, EMPower is aimed at increasing breastfeeding rates ...
(Date:5/29/2015)... On May 21, 2015, Elle Magazine in article titled ... Botox ?” reported on the four most commonly searched beauty ... to determine these results and then sought expert help to ... example, is how to keep neck skin tight . ... the appropriate age to start receiving Botox injections . ...
(Date:5/29/2015)... The Healthcare Delivery Institute at HORNE ... Training Program (ATP) in Healthcare Delivery Improvement. The ... health care organization ranging from clinicians to CFOs, ... quality improvement in the health care environment. The ... internationally recognized Advanced Training Program at Intermountain Healthcare. ...
(Date:5/29/2015)... 29, 2015 The print component of ... circulation of approximately 250,000 and an estimated readership of ... vast social media strategy, and across a network of ... digital version of the campaign, click here. ... publication. Inside, the actress, model and producer details her ...
(Date:5/29/2015)... Shaila Jiwa, a physiotherapist from Burnaby ... stated in a new announcement that patients of urinary ... commonly seen as a tabooed topic to talk about ... like Shaila Jiwa try to encourage people to come ... is a condition that can be classified under two ...
Breaking Medicine News(10 mins):Health News:Abington Hospital Selected to Join Baby-Friendly Hospital Initiative 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Patients of Urinary Incontinence Should Not "Hide And Suffer," States Physiotherapist from Burnaby Physiotherapy Clinic 2
... , CHICAGO, July 16 GoHealthInsurance ... for quality health insurance, through a network of technology-enabled health insurance ... Owens as Senior Vice President. , , ... insurance, health care and financial industries, and has significant expertise in ...
... 16 Immucor, Inc. (Nasdaq: BLUD ), a ... transfusion industry, today announced that Geoffrey S. Crouse has been ... , In this newly created position, ... as well as sales, marketing and customer service. Mr. Crouse ...
... genes alone aren,t destiny, study finds , THURSDAY, July ... problems are influenced by both genetic and environmental factors, ... on genetic and environmental influences on behavior was often ... of psychiatry, psychology, and human and molecular genetics at ...
... , , BATON ROUGE, ... first of four new facilities designed to help the organization boost ... new Red Cross buildings, located in Baton Rouge, LA, Tallahassee, FL, ... by a $25 million gift from the Kuwaiti people through the ...
... Ohio, July 16 Bedford Laboratories(TM), a division of Ben Venue ... USP. This product is AP rated and is equivalent to ... to treat several types of infections caused by susceptible bacteria. , ... http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO ) , , ...
... spread, CDC says , THURSDAY, July 16 (HealthDay News) ... of infant illness in the United States, could be ... where infections are likely to spread and by the ... A team including scientists from the U.S. Centers for ...
Cached Medicine News:Health News:GoHealthInsurance Announces Appointment of Mike Owens as Senior Vice President 2Health News:Immucor Appoints Chief Operating Officer 2Health News:Teen Behaviors Stem From Genetics, Environment 2Health News:Gulf Coast Residents to Benefit From Gift of Kuwaiti People 2Health News:Bedford Laboratories(TM) to Begin Shipping Ceftriaxone for Injection USP 2Health News:New Insights Could Help Shield Babies From Diarrhea Bug 2
Terumo's Optitorque offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective catheter. Catheter material used is polyurethane (TRICOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: